Antonia, S. J., Gettinger, S. N., Goldman, J., Brahmer, J., Borghaei, H., Chow, L. Q., … Hellmann, M. D. (2016). CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. In JOURNAL OF THORACIC ONCOLOGY (Vol. 11, pp. S250–S251). ELSEVIER SCIENCE INC.

Antonia, Scott J., Scott N. Gettinger, Jonathan Goldman, Julie Brahmer, Hossein Borghaei, Laura Q. Chow, Neal E. Ready, et al. “CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC.” In JOURNAL OF THORACIC ONCOLOGY, 11:S250–51. ELSEVIER SCIENCE INC, 2016.

Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, et al. CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. In: JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC; 2016. p. S250–1.

Antonia, Scott J., et al. “CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC.” JOURNAL OF THORACIC ONCOLOGY, vol. 11, no. 11, ELSEVIER SCIENCE INC, 2016, pp. S250–51.

Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Hellmann MD. CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC; 2016. p. S250–S251.